(RTTNews) - BioLineRx Ltd. (BLRX) a commercial-stage biopharmaceutical company enters into a license agreement to develop and commercialize APHEXDA. The company receives a $10 million upfront payment ...
BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ: BLRX) reported first quarter 2026 financial and operational results in a May 27 th press release. For the quarter, it produced license ...
Bioline RX Ltd Sponsored ADR (BLRX) has released an update. BioLineRx Ltd. has reported a successful first quarter in 2024, with a notable uptake of their newly approved therapy APHEXDA® and progress ...
Credit: BioLineRx. Aphexda is expected to be available in September 2023. The Food and Drug Administration (FDA) has approved Aphexda ™ (motixafortide) in combination with filgrastim (granulocyte ...
The recent FDA approval of Aphexda combined with filgrastim improved the collection of stem cells in patients with multiple myeloma. Stem cell transplantation is an important treatment method for ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved motixafortide combined with filgrastim for mobilization of hematopoietic stem cells into ...
After 10 years of stagnation, a new FDA approval could help more cancer patients become eligible for stem cell transplants. Monday, Israeli drugmaker BioLineRx said the FDA approved motixafortide—also ...
The FDA has approved Aphexda plus filgrastim for the mobilization of hematopoietic stem cells in patients with multiple myeloma. The Food and Drug Administration (FDA) has approved Aphexda ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results